Key facts
- This page summarizes Enavate Sciences GP, LLC's Form 4 filing for Camp4 Therapeutics Corp (CAMP).
- 3 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 17 Oct 2024, 16:15.
Enavate Sciences GP, LLC - 15 Oct 2024 Form 4 Insider Report for Camp4 Therapeutics Corp (CAMP)
- Reporting relationship
- 10%+ Owner
- Issuer ticker
- CAMP
- Reported as of
- 15 Oct 2024
- Net transaction value
- +$14,999,996
- SEC form
- 4
- Accepted by SEC
- 17 Oct 2024, 16:15:05 UTC
- Prior SEC filing
- 10 Oct 2024
- Source filing
- View source filing
- Reporting owner signature
- Enavate Sciences GP, LLC, By: /s/ James P. Boylan, Manager
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Enavate Sciences GP, LLC filed Form 4 for Camp4 Therapeutics Corp (CAMP) on 17 Oct 2024.
Change
- Previous filing in this sequence was filed on 10 Oct 2024.
- Current net transaction value: +$14,999,996.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CAMP
transaction
Common Stock
Conversion of derivative security
- Transaction value
- Shares
- +2,422,166
- Change %
- Price
- Shares after
- 2,422,166
- Date
- 15 Oct 2024
- Ownership
- By Everest Aggregator, LP
- Footnotes
- F1, F2
CAMP
transaction
Common Stock
Purchase
- Transaction value
- $14,999,996
- Shares
- +1,363,636
- Change %
- +56%
- Price
- $11.00
- Shares after
- 3,785,802
- Date
- 15 Oct 2024
- Ownership
- By Everest Aggregator, LP
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CAMP
transaction
Derivative
Series B Preferred Stock
Conversion of derivative security
- Transaction value
- Shares
- -27,166,530
- Change %
- -100%
- Price
- Shares after
- 0
- Date
- 15 Oct 2024
- Ownership
- By Everest Aggregator, LP
- Underlying class
- Common Stock
- Underlying amount
- 2,422,166
- Exercise price
- Footnotes
- F1, F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Each share of Series B Preferred Stock (the "Preferred Stock") converted into shares of Common Stock of the Issuer on a 11.2158-for-one basis without payment of further consideration. Immediately prior to the closing of the Issuer's initial public offering, the Preferred Stock was converted into the number of shares of Common Stock of the Issuer shown in column 7 of Table II. The Preferred Stock had no expiration date.
Footnote F2
Shares are directly held by Everest Aggregator, LP ("Everest"). Enavate Sciences GP, LLC ("Enavate") is the general partner of Everest and may be deemed to share voting and investment power with respect to the shares held by Everest. Enavate disclaims beneficial ownership of these shares except to the extent of its pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purpose.